|Description||MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans along with a minipig skin biopsy model. It was developed by Merck. It was used to treat rheumatoid arthritis in phase II clinical trials and plaque psoriasis in phase I clinical trials, but it has no recent research progress.|
|Solubility||Soluble in DMSO, not in water|
|Application||MK0873 was used to treat rheumatoid arthritis and plaque psoriasis.|
|Quality Standard||In-house standard|
|Boiling Point||772.1±60.0 °C | Condition: Press: 760 Torr|
|Density||1.34±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||MK0873 was developed by Merck. It was used to treat rheumatoid arthritis in phase II clinical trials and plaque psoriasis in phase I clinical trials, but it has no recent research progress.|
Crisaborole is a novel PDE-4 inhibitor used as a nonsteroidal topical medication for the treatment of mild-to-moderate atopic dermatitis (eczema). Crisaborole s...
CI-1044, a selective PDE4 inhibitor, inhibits in vitro LPS-induced TNF-alpha release in whole blood from COPD patients better than rolipram and cilomilast and s...
Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 μM and 0.8 μM respectively.
GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to el...
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selec...
MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition.
Selective phosphodiesterase 4 (PDE4) inhibitor. Antiasthmatic; used in treatment of chronic obstructive pulmonary disease.
S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous ...
CP-220629, a Pyrazolopyridin derivative, has been found to be a Type 4 cyclic nucleotide phosphodiesterase inhibitor that was once studied as an anti-inflammato...
Tilivapram, a pyridine derivative, has been found to be a phosphodiesterase IV inhibitor that could probably be used in studying its bioactivities in sorts of a...
NVP-ABE171 is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D ...
Apremilast (CC-10004)is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneo...
Oglemilast is a potent PDE4 inhibitor and under clinical studies in the treatment of allergen-induced asthma.
Roflumilast has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such ...
AN3199, a PDE4 inhibitor, was once studied as an anti-inflammatory agent. IC50: 94.5 nM
L-869298 is a high potent and selective PDE4 inhibitor, acts as a Type 4 cyclic nucleotide phosphodiesterase inhibitor.
GSK256066 2,2,2-trifluoroacetic acid
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold...
Ronomilast is type 4 cyclic nucleotide phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
CP-671305 is a potent and selective inhibitor of PDE4.
MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans...